Multi-dimensional, High-throughput Small-molecule Screening Platforms for Protein-misfolding Diseases

A cell-based robust assay system to screen small molecules as modifier of aggregation potential of alpha-synuclein, the aggregating protein in Parkinson's disease.

This technology brings forward a cell-based robust assay system to screen small molecules as modifier of aggregation potential of alpha-synuclein, the aggregating protein in Parkinson's disease. This is a screening platform that mimics the fundamental events of protein aggregation and disease in cultured cells.
It provides a Cell-based assay system for α-synuclein amyloids wherein Unique combination of two synuclein mutations is used and which avoids animal use completely. This is a Robust fluorescence spectroscopy/ microscopy based assay for amyloid    formation.    

1. Cell-based assay system for α-synuclein amyloids
2. Robust fluorescence spectroscopy/ microscopy based assay for amyloid    formation
3. High throughput
4. Avoids animal use, no ethical issues
5. Reduced steps (no transfection), much better fluorescence, robust assay
6. Cost effective – ₹ 20 per reaction*